CJC-1295 (No DAC)
CJC-1295 No DAC is a short-acting research peptide designed to imitate part of growth hormone-releasing hormone. Researchers are interested in its possible influence on pituitary signaling, growth hormone release, and IGF-1, although direct research on this specific form remains extremely limited.
CJC-1295 NO DAC AT A GLANCE
WHAT IS CJC-1295 NO DAC?
CJC-1295 No DAC is a laboratory-created peptide based on the first 29 amino acids of growth hormone-releasing hormone, commonly called GHRH. It contains several changes intended to make the peptide more resistant to rapid breakdown than the natural hormone fragment.
The name “No DAC” means it does not contain the Drug Affinity Complex found in long-acting CJC-1295 DAC. It is also called CJC-1295 free base, CJC-1295 acetate, tetra-substituted GRF 1-29, or Modified GRF 1-29, although these names are not always used consistently.
HOW DOES CJC-1295 NO DAC WORK?
Natural GHRH travels from the brain to the pituitary gland, where it helps signal the release of growth hormone. CJC-1295 No DAC was designed to imitate this process by interacting with the same type of signaling pathway.
Unlike the DAC version, it does not contain the added structure that attaches the peptide to albumin and keeps it circulating for several days. It is therefore expected to have shorter activity, but its exact behavior and half-life have not been established through controlled human studies.
Areas of Research
Research interest in CJC-1295 No DAC centers on hormone communication between the brain and pituitary gland. Much of this interest is based on its structure and on broader GHRH research rather than direct studies of the peptide itself.
GROWTH HORMONE SIGNALING
Exploring how GHRH-related peptides may influence signals that encourage growth hormone release.
PITUITARY ACTIVITY
Studying how the pituitary gland responds to shorter-acting hormone signals.
IGF-1 RESEARCH
Examining the relationship between growth hormone activity and the production of IGF-1.
PEPTIDE DURATION
Comparing a peptide without albumin-binding DAC to longer-lasting CJC-1295 DAC.
Research Highlights
Scientists have studied natural GHRH 1-29 and related analogues to learn how structural changes affect growth hormone release and peptide stability. This work helped researchers develop modified sequences that resist breakdown while continuing to resemble the active portion of natural GHRH.
However, research specifically involving CJC-1295 No DAC is difficult to identify. The FDA found no studies establishing the pharmacological activity of CJC-1295 free base or acetate and no human clinical safety information for these forms. Findings from CJC-1295 DAC studies should not be applied automatically to the No DAC version.
WHAT IS CJC-1295 NO DAC MOST COMMONLY RESEARCHED FOR?
CJC-1295 No DAC is commonly associated with research into growth hormone release, pituitary activity, and GHRH-related signaling. Scientists are interested in how a shorter-acting signal may differ from the prolonged activity created by DAC. Direct evidence involving this specific peptide remains very limited, however.
HOW DOES CJC-1295 NO DAC FIT INTO PEPTIDE RESEARCH?
This peptide fits into research exploring how small changes to a natural hormone sequence can affect stability and biological activity. Its structure is based on the active portion of GHRH but includes four amino-acid substitutions. Researchers can examine these changes to better understand peptide breakdown and pituitary signaling.
WHAT MAKES CJC-1295 NO DAC UNIQUE?
Its lack of an albumin-binding DAC structure is the most important distinction. CJC-1295 DAC was designed to remain active for several days, while the No DAC form is expected to produce a shorter signal. This difference means the two versions should be treated as separate research subjects rather than interchangeable names.
CAN CJC-1295 NO DAC BE RESEARCHED ALONGSIDE OTHER PEPTIDES?
Researchers may compare CJC-1295 No DAC with CJC-1295 DAC and other GHRH-related peptides such as sermorelin and tesamorelin. It is also frequently discussed with ipamorelin, which acts through a different receptor pathway. Comparing these substances can help researchers examine different forms of pituitary signaling.
WHAT HAVE RESEARCHERS LEARNED ABOUT CJC-1295 NO DAC SO FAR?
Researchers understand its 29-amino-acid structure and how it differs chemically from the DAC version. Far less is known about how the No DAC form behaves in living systems. The FDA found no direct pharmacological studies or human clinical safety data establishing the activity of CJC-1295 free base or acetate.
IS RESEARCH ON CJC-1295 NO DAC CONTINUING TODAY?
CJC-1295 No DAC continues to appear in peptide research discussions, but published evidence remains scarce and naming inconsistencies make the available information difficult to interpret. More clearly identified laboratory and human studies would be needed to establish its activity, duration, safety, and possible research applications.